Analysts Offer Predictions for CRSP FY2024 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors on Monday, February 3rd. HC Wainwright analyst M. Kapoor anticipates that the company will earn ($4.83) per share for the year. HC Wainwright currently has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.10) per share. HC Wainwright also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($0.98) EPS, Q1 2025 earnings at ($1.11) EPS, Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.11) EPS, Q4 2025 earnings at ($1.03) EPS and FY2025 earnings at ($4.25) EPS.

Several other analysts also recently issued reports on CRSP. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. JMP Securities reissued a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday, December 20th. Bank of America cut their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Royal Bank of Canada reissued a “sector perform” rating and set a $53.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Finally, Chardan Capital reissued a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $77.59.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $40.49 on Wednesday. The stock has a market capitalization of $3.46 billion, a P/E ratio of -14.31 and a beta of 1.67. CRISPR Therapeutics has a 1 year low of $36.52 and a 1 year high of $91.10. The business’s fifty day moving average is $43.37 and its two-hundred day moving average is $46.85.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter in the prior year, the company earned ($1.41) earnings per share.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of hedge funds have recently bought and sold shares of the company. ARK Investment Management LLC boosted its holdings in CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after acquiring an additional 1,474,439 shares during the period. State Street Corp boosted its holdings in CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after acquiring an additional 599,304 shares during the period. FMR LLC raised its position in shares of CRISPR Therapeutics by 1.0% during the third quarter. FMR LLC now owns 2,376,166 shares of the company’s stock valued at $111,632,000 after buying an additional 23,075 shares during the last quarter. Geode Capital Management LLC raised its position in shares of CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after buying an additional 35,196 shares during the last quarter. Finally, Baker BROS. Advisors LP raised its position in shares of CRISPR Therapeutics by 743.1% during the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after buying an additional 743,075 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is currently owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.